Avalyn Pharma (NASDAQ:AVLN) Hits New 52-Week High Following Better-Than-Expected Earnings
I'm LongbridgeAI, I can summarize articles.Avalyn Pharma (NASDAQ:AVLN) shares hit a new 52-week high of $39.99 after reporting better-than-expected earnings, with EPS of ($0.98) beating estimates of ($1.03). The stock closed at $37.38. Analysts from Morgan Stanley, Evercore, and Jefferies initiated coverage with 'overweight', 'outperform', and 'buy' ratings respectively, setting price targets between $51 and $53. Bank of New York Mellon also acquired a new position in the company.
Shares of Avalyn Pharma Inc. (NASDAQ:AVLN - Get Free Report) reached a new 52-week high during mid-day trading on Thursday following a better than expected earnings announcement. The company traded as high as $39.99 and last traded at $37.38, with a volume of 378235 shares traded. The stock had previously closed at $35.46.
Get Avalyn Pharma alerts:
The company reported ($0.98) earnings per share for the quarter, topping analysts' consensus estimates of ($1.03) by $0.05.
Analysts Set New Price Targets
Several brokerages recently weighed in on AVLN. Zacks Research raised shares of Avalyn Pharma to a "hold" rating in a research report on Wednesday, May 27th. Morgan Stanley began coverage on shares of Avalyn Pharma in a research note on Tuesday, May 26th. They set an "overweight" rating and a $53.00 price target on the stock. Evercore began coverage on shares of Avalyn Pharma in a report on Tuesday, May 26th. They set an "outperform" rating and a $51.00 price target on the stock. Jefferies Financial Group assumed coverage on shares of Avalyn Pharma in a research note on Monday, May 25th. They issued a "buy" rating and a $52.00 price objective for the company. Finally, Wall Street Zen upgraded shares of Avalyn Pharma to a "hold" rating in a report on Saturday, May 9th. Two equities research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $59.00.
Check Out Our Latest Research Report on Avalyn Pharma
Institutional Trading of Avalyn Pharma
A hedge fund recently bought a new position in Avalyn Pharma stock. Bank of New York Mellon Corp acquired a new position in shares of Avalyn Pharma Inc. (NASDAQ:AVLN - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 40,140 shares of the company's stock, valued at approximately $1,321,000. Bank of New York Mellon Corp owned 0.09% of Avalyn Pharma at the end of the most recent quarter.
Avalyn Pharma Price Performance
The stock's 50 day simple moving average is $29.71. The stock has a market cap of $1.66 billion and a price-to-earnings ratio of -1.71.
Avalyn Pharma Company Profile
(Get Free Report)We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.
Further Reading
- Five stocks we like better than Avalyn Pharma
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Add As Preferred Source
Should You Invest $1,000 in Avalyn Pharma Right Now?
Before you consider Avalyn Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avalyn Pharma wasn't on the list.
While Avalyn Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here